Evaluating the Efficacy of Different Treatment Intensities in Nasopharyngeal Carcinoma Patients: A Nationwide Cancer Registry-Based Study

被引:2
|
作者
Jen, Chung-Wen [1 ,2 ]
Chan, Han-Ching [1 ]
Chiang, Chun-Ju [1 ,3 ]
Lee, Wen-Chung [1 ,3 ,4 ]
Lu, Tzu-Pin [1 ,4 ]
Cheng, Skye Hung-Chun [2 ,5 ]
机构
[1] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei, Taiwan
[2] Taitung Christian Hosp, Dept Radiat Oncol, Taitung City, Taiwan
[3] Taiwan Canc Registry, Taipei, Taiwan
[4] Natl Taiwan Univ, Inst Hlth Data Analyt & Stat, Taipei City, Taiwan
[5] Sun Yat Sen Canc Ctr, Koo Fdn, Dept Radiat Oncol, Taipei City, Taiwan
关键词
Nasopharyngeal carcinoma; Radiotherapy; Concurrent chemoradiotherapy; Adjuvant chemotherapy; Induction chemotherapy; CONCURRENT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; RADIOTHERAPY; SURVIVAL; OUTCOMES;
D O I
10.1245/s10434-024-16145-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe aim of this study was to evaluate the efficacy of different treatment intensities (TIs) in patients with nasopharyngeal carcinoma (NPC).MethodsThe study assessed newly diagnosed, non-metastatic NPC patients from the Taiwan Cancer Registry between 2010 and 2017. TIs were divided into four groups: TI1 [radiotherapy (RT) alone or induction chemotherapy (IC) followed by RT); TI2 (concurrent chemoradiotherapy (CRT) alone); TI3 (IC followed by CRT or CRT followed by adjuvant chemotherapy (AC)]; and TI4 (IC followed by CRT followed by AC). The primary outcome was cancer-specific survival (CSS).ResultsThe study included 9863 patients. For stage I-II NPC patients, there was no significant difference in CSS among the different TI groups. For stage III patients, those receiving TI3 had better CSS (hazard ratio [HR] 0.69) compared with those receiving TI1. No significant differences in CSS were noted among those receiving TI2, TI3, and TI4. For stage IVA-B patients, those receiving TI2 (HR 0.70), TI3 (HR 0.49), and TI4 (HR 0.43) had better CSS compared with those receiving TI1. Compared with stage IVA-B patients receiving TI2, those receiving TI3 (HR 0.70) and TI4 (HR 0.61) had significantly better CSS. No differences in CSS were noted between those receiving TI3 and TI4.ConclusionsFor stage I-II NPC patients, RT alone is appropriate. For stage III and IVA-B patients, IC + CRT or CRT + AC may be needed to achieve optimal outcomes. No advantage of IC + CRT + AC over IC + CRT or CRT + AC was observed.
引用
收藏
页码:9125 / 9133
页数:9
相关论文
共 50 条
  • [31] OUTCOMES AFTER INTRAVENOUS THROMBOLYSIS IN YOUNG STROKE PATIENTS: A NATIONWIDE REGISTRY-BASED STUDY
    Zheng, Y.
    Zheng, H.
    Ho, A.
    Yeo, L.
    Ong, M.
    Tan, B.
    INTERNATIONAL JOURNAL OF STROKE, 2023, 18 (03) : 394 - 395
  • [32] A Nation-Wide Cancer Registry-Based Study of Adenosquamous Carcinoma in Taiwan
    Lan, Yuan-Tzu
    Huang, Kuo-Hung
    Liu, Chien-An
    Tai, Ling-Chen
    Chen, Ming-Huang
    Chao, Yee
    Li, Anna Fen-Yau
    Chiou, Shih-Hwa
    Shyr, Yi-Ming
    Wu, Chew-Wun
    Fang, Wen-Liang
    PLOS ONE, 2015, 10 (10):
  • [33] Statin use and risk of endometrial cancer: a nationwide registry-based case-control study
    Sperling, Cecilie D.
    Verdoodt, Freija
    Friis, Soren
    Dehlendorff, Christian
    Kjaer, Susanne K.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2017, 96 (02) : 144 - 149
  • [34] Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study
    Lee, Sae Byul
    Ko, Seung Sang
    Park, Chan Heun
    Nam, Seok Jin
    Choi, Jung Eun
    Jung, Yong Sik
    Park, Woo-Chan
    Son, Byung Ho
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (02) : 273 - 282
  • [35] The non-fatal burden of cancer in Belgium, 2004–2019: a nationwide registry-based study
    Vanessa Gorasso
    Geert Silversmit
    Marc Arbyn
    Astrid Cornez
    Robby De Pauw
    Delphine De Smedt
    Ian Grant
    Grant M. A. Wyper
    Brecht Devleesschauwer
    Niko Speybroeck
    BMC Cancer, 22
  • [36] Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway
    Stoer, Nathalie C.
    Bouche, Gauthier
    Pantziarka, Pan
    Sloan, Erica K.
    Andreassen, Bettina K.
    Botteri, Edoardo
    ACTA ONCOLOGICA, 2021, 60 (09) : 1146 - 1153
  • [37] Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study
    Sae Byul Lee
    Seung Sang Ko
    Chan Heun Park
    Seok Jin Nam
    Jung Eun Choi
    Yong Sik Jung
    Woo-Chan Park
    Byung Ho Son
    Breast Cancer Research and Treatment, 2018, 172 : 273 - 282
  • [38] Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study
    Helgadottir, Hildur
    Ny, Lars
    Ullenhag, Gustav J.
    Falkenius, Johan
    Mikiver, Rasmus
    Bagge, Roger Olofsson
    Isaksson, Karolin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (09): : 1077 - 1084
  • [39] A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer
    Groenendijk, Floris H.
    Jager, Agnes
    Cardoso, Fatima
    van Deurzen, Carolien H. M.
    BREAST, 2018, 38 : 125 - 131
  • [40] Intraductal Papillary Mucinous Neoplasms of The Pancreas: A Nationwide Registry-Based Study
    Aronsson, L.
    Andersson, B.
    Andersson, R.
    Tingstedt, B.
    Bratlie, S. O.
    Ansari, D.
    SCANDINAVIAN JOURNAL OF SURGERY, 2018, 107 (04) : 302 - 307